We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has asked Bayer to add a black box warning to its calcium channel blocker Nimotop that states the drug should not be administered intravenously.